Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is funded by PER®.
Proteolysis-Targeting Chimera (PROTAC) Therapy for Cancer
Release Date: December 3, 2021
Expiration Date: December 3, 2022
This continuing medical education (CME) activity provides expert insight regarding proteolysis-targeting chimera (PROTAC) therapy for the treatment of cancer. This program reviews the mechanism by which PROTACs function, their role in the treatment of cancer, early clinical trial data for emerging PROTACs, and safety considerations.
Acknowledgement of Commercial Support
This activity is funded by PER®.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanism of action of proteolysis-targeting chimera (PROTAC) therapy for the treatment of cancer.
- Explain the rationale for using PROTAC therapy for the treatment of cancer.
- Assess key data from ongoing clinical trials evaluating PROTAC therapy for the treatment of cancer.
Faculty, Staff, and Planners’ DisclosuresThe staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
Professor of Medicine and Urology
Director, Genitourinary Oncology Research Program
Co-Director, Cancer Signal Transduction Program
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosures: Grant Research Support: Ada Cap (Advanced Accelerator Applications), Agensys Inc., Astellas Pharma, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly and Company, Endocyte, Genentech, Gilead Sciences, Innocrin Pharmaceuticals, MedImmune, Medivation, Merck & Co., Mirati Therapeutics, Novartis, Pfizer, Progenics Pharmaceuticals, Replimune Group, Roche, Sanofi Aventis, Seagen. Consultant: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas Pharma, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen Pharmaceuticals, Mirati Therapeutics, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seagen, UroGen Pharma. Stock/Shareholder: Bellicum Pharmaceuticals (sold July 2020), Tyme Technologies(sold October 2019).
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep processOff-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for accredited continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.